原发性甲状旁腺功能亢进症对心血管系统影响的相关研究进展
Research Progress on the Effect of Primary Hyperparathyroidism on Cardiovascular System
DOI: 10.12677/acm.2024.143927, PDF,   
作者: 艾丽斐然·艾克帕尔：新疆医科大学研究生学院，新疆 乌鲁木齐；郭艳英*：新疆维吾尔自治区人民医院内分泌科，新疆糖尿病临床医学研究中心，新疆 乌鲁木齐
关键词: 原发性甲状旁腺功能亢进症；心血管疾病；甲状旁腺激素；钙离子；Primary Hyperparathyroidism； Cardiovascular Disease； Parathyroid Hormone； Calcium Ion
摘要: 原发性甲状旁腺功能亢进症是累及全身多个系统的内分泌疾病，通过甲状旁腺激素与钙离子的作用，原发性甲状旁腺功能亢进症除了对经典靶器官(骨骼及肾脏)的损害，对心血管疾病也有一定的损害，并可能导致发生心血管不良事件，且与死亡率也有相关性。本综述也探讨了关于PTX术后对心血管疾病的改善程度，但改善程度结果不一致。故为了今后原发性甲状旁腺功能亢进症导致的心血管疾病需要临床医生在工作中引起重视，现就原发性甲状旁腺功能亢进症的流行病学、发病机制及治疗方法进行综述，旨在为原发性甲状旁腺功能亢进症对心血管系统的影响提供理论依据。
Abstract: Primary hyperparathyroidism is an endocrine disease involving many systems of the whole body. Through the action of parathyroid hormone and calcium ion, primary hyperparathyroidism not only damages the classical target organs (bones and kidneys), but also has certain damage to cardiovascular disease, and may lead to cardiovascular adverse events, and is also related to mortality. This review also discusses the degree of improvement of cardiovascular disease after PTX, but the results are not consistent. Therefore, in order to pay attention to the cardiovascular disease caused by primary hyperparathyroidism in the future, the epidemiology, pathogenesis and treatment of primary hyperparathyroidism are reviewed in order to provide theoretical basis for the effect of primary hyperparathyroidism on cardiovascular system.
文章引用：艾丽斐然·艾克帕尔, 郭艳英. 原发性甲状旁腺功能亢进症对心血管系统影响的相关研究进展[J]. 临床医学进展, 2024, 14(3): 1942-1948. https://doi.org/10.12677/acm.2024.143927

参考文献

[1] Zhu, C.Y., Sturgeon, C. and Yeh, M.W. (2020) Diagnosis and Management of Primary Hyperparathyroidism. JAMA, 323, 1186-1187. [Google Scholar] [CrossRef] [PubMed]
[2] Nilsson, I.L. (2019) Primary Hyperparathyroidism: Should Surgery Be Performed on All Patients? Current Evidence and Residual Uncertainties. Journal of Internal Medicine, 285, 149-164. [Google Scholar] [CrossRef] [PubMed]
[3] Hagström, E., Hellman, P., Larsson, T.E., et al. (2009) Plasma Parathyroid Hormone and the Risk of Cardiovascular Mortality in the Community. Circulation, 119, 2765-2771. [Google Scholar] [CrossRef] 
[4] Pepe, J., Cipriani, C., Sonato, C., et al. (2017) Cardiovascular Manifestations of Primary Hyperparathyroidism: A Narrative Review. European Journal of Endocrinology, 177, R297-R308. [Google Scholar] [CrossRef] 
[5] Fujii, H. (2018) Association between Parathyroid Hormone and Cardiovascular Disease. Therapeutic Apheresis and Dialysis, 22, 236-241. [Google Scholar] [CrossRef] [PubMed]
[6] 何春华, 王金芳, 王清国. 原发性甲状旁腺功能亢进症患者的心血管风险研究进展[J]. 中国全科医学, 2021, 24(33): 4287-4292.
[7] Deshmukh, H., Barker, E., Anbarasan, T., et al. (2018) Calcium Channel Blockers Are Associated with Improved Survival and Lower Cardiovascular Mortality in Patients with Renovascular Disease. Cardiovascular Therapeutics, 36, e12474. [Google Scholar] [CrossRef] [PubMed]
[8] Touyz, R.M., Alves-Lopes, R., Rios, F.J., et al. (2018) Vascular Smooth Muscle Contraction in Hypertension. Cardiovascular Research, 114, 529-539. [Google Scholar] [CrossRef] [PubMed]
[9] 梁美云, 冯正平. 钙与心脑血管疾病的关系及其作用机制[J]. 中华骨质疏松和骨矿盐疾病杂志, 2020, 13(2): 177-183.
[10] 于凤至, 孙朋, 刘淑卉. G蛋白偶联受体在运动调控动脉舒张过程中的机制[J]. 中国体育科技, 2021, 57(10): 79-88.
[11] Kurabayashi, M, (2019) Molecular Mechanism of Vascular Calcification. Clinical Calcium, 29, 157-163.
[12] 魏伟荣, 华山, 吴克勤, 等. 血清甲状旁腺激素对老年高血压患者心脏舒张功能的影响[J]. 中国临床保健杂志, 2020, 23(2): 191-194.
[13] Fisher, S.B, and Perrier, N.D, (2020) Primary Hyperparathyroidism and Hypertension. Gland Surgery, 9, 142-149. [Google Scholar] [CrossRef] [PubMed]
[14] Osto, E., Fallo, F., Pelizzo, M.R., et al. (2012) Coronary Microvascular Dysfunction Induced by Primary Hyperparathyroidism Is Restored after Parathyroidectomy. Circulation, 126, 1031-1039. [Google Scholar] [CrossRef] 
[15] 李晨, 李蓉, 李立. 动脉粥样硬化研究: 缘起、观点及发展趋势[J]. 临床医学进展, 2022, 12(5): 4934-4950.
[16] Frey, S., Mirallié, É., Cariou, B. and Blanchard, C. (2021) Impact of Parathyroidectomy on Cardiovascular Risk in Primary Hyperparathyroidism: A Narrative Review. Nutrition, Metabolism, and Cardiovascular Diseases, 31, 981-996. [Google Scholar] [CrossRef] [PubMed]
[17] Koubaity, O., Mandry, D., Nguyen-Thi, P.L., et al. (2020) Coronary Artery Disease Is More Severe in Patients with Primary Hyperparathyroidism. Surgery, 167, 149-154. [Google Scholar] [CrossRef] [PubMed]
[18] Beysel, S., Caliskan, M., Kizilgul, M., et al. (2019) Parathyroidectomy Improves Cardiovascular Risk Factors in Normocalcemic and Hypercalcemic Primary Hyperparathyroidism. BMC Cardiovascular Disorders, 19, Article No. 106. [Google Scholar] [CrossRef] [PubMed]
[19] Kim, H.L., Chung, J., Kim, K.J., et al. (2022) Lifestyle Modification in the Management of Metabolic Syndrome: Statement from Korean Society of CardioMetabolic Syndrome (KSCMS). Korean Circulation Journal, 52, 93-109. [Google Scholar] [CrossRef] [PubMed]
[20] Procopio, M., Barale, M., Bertaina, S., et al. (2014) Cardiovascular Risk and Metabolic Syndrome in Primary Hyperparathyroidism and Their Correlation to Different Clinical Forms. Endocrine, 47, 581-589. [Google Scholar] [CrossRef] [PubMed]
[21] YenerOzturk, F., Erol, S., Canat, M.M., et al. (2016) Patients with Normocalcemic Primary Hyperparathyroidism May Have Similar Metabolic Profile as Hypercalcemic Patients. Endocrine Journal, 63, 111-118. [Google Scholar] [CrossRef] 
[22] Reid, I.R., Gamble, G.D. and Bolland, M.J. (2016) Circulating Calcium Concentrations, Vascular Disease and Mortality: A Systematic Review. Journal of Internal Medicine, 279, 524-540. [Google Scholar] [CrossRef] [PubMed]
[23] Kobylecki, C.J., Nordestgaard, B.G. and Afzal, S. (2021) Plasma Ionized Calcium and Risk of Cardiovascular Disease: 106 774 Individuals from the Copenhagen General Population Study. Clinical Chemistry, 67, 265-275. [Google Scholar] [CrossRef] [PubMed]
[24] Bandeira, F., De Moura Nóbrega, J., De Oliveira, L.B., et al. (2022) Medical Management of Primary Hyperparathyroidism. Archives of Endocrinology and Metabolism, 66, 689-693. [Google Scholar] [CrossRef] [PubMed]
[25] Orr-Walker, B.J., Evans, M.C., Clearwater, J.M., et al. (2000) Effects of Hormone Replacement Therapy on Bone Mineral Density in Postmenopausal Women with Primary Hyperparathyroidism: Four-Year Follow-Up and Comparison with Healthy Postmenopausal Women. Archives of Internal Medicine, 160, 2161-2166. [Google Scholar] [CrossRef] [PubMed]
[26] Rubin, M.R., Lee, K.H., McMahon, D.J. and Silverberg, S.J. (2003) Raloxifene Lowers Serum Calcium and Markers of Bone Turnover in Postmenopausal Women with Primary Hyperparathyroidism. The Journal of Clinical Endocrinology and Metabolism, 88, 1174-1178. [Google Scholar] [CrossRef] [PubMed]
[27] ACTIVE研究工作组. 西那卡塞治疗中国维持性血液透析继发性甲状旁腺功能亢进的多中心临床研究(ACTIVE)方案[J]. 肾脏病与透析肾移植杂志, 2020, 29(5): 478-483.
[28] Rydberg, E., Birgander, M., Bondeson, A.G., et al. (2010) Effect of Successful Parathyroidectomy on 24-Hour Ambulatory Blood Pressure in Patients with Primary Hyperparathyroidism. International Journal of Cardiology, 142, 15-21. [Google Scholar] [CrossRef] [PubMed]
[29] Graff-Baker, A.N., Bridges, L.T., Chen, Q., et al. (2020) Parathyroidectomy for Patients with Primary Hyperparathyroidism and Associations with Hypertension. JAMA Surgery, 155, 32-39. [Google Scholar] [CrossRef] [PubMed]
[30] Ejlsmark-Svensson, H., Rolighed, L. and Rejnmark, L. (2019) Effect of Parathyroidectomy on Cardiovascular Risk Factors in Primary Hyperparathyroidism: A Randomized Clinical Trial. The Journal of Clinical Endocrinology and Metabolism, 104, 3223-3232. [Google Scholar] [CrossRef] [PubMed]
[31] Karakose, M., Caliskan, M., Arslan, M.S., et al. (2017) The Impact of Parathyroidectomy on Serum ADAMTS1, ADAMTS4 Levels, Insulin Resistance, and Subclinical Cardiovascular Disease in Primary Hyperparathyroidism. Endocrine, 55, 283-288. [Google Scholar] [CrossRef] [PubMed]
[32] Norenstedt, S., Pernow, Y., Brismar, K., et al. (2013) Primary Hyperparathyroidism and Metabolic Risk Factors, Impact of Parathyroidectomy and Vitamin D Supplementation, and Results of A Randomized Double-Blind Study. European Journal of Endocrinology, 169, 795-804. [Google Scholar] [CrossRef] 
[33] Luigi, P., Chiara, F.M., Laura, Z., et al. (2012) Arterial Hypertension, Metabolic Syndrome and Subclinical Cardiovascular Organ Damage in Patients with Asymptomatic Primary Hyperparathyroidism before and after Parathyroidectomy: Preliminary Results. International Journal of Endocrinology, 2012, Article ID: 408295. [Google Scholar] [CrossRef] [PubMed]
[34] Farahnak, P., Lärfars, G., Sten-Linder, M. and Nilsson, I.L. (2011) Mild Primary Hyperparathyroidism: Vitamin D Deficiency and Cardiovascular Risk Markers. The Journal of Clinical Endocrinology and Metabolism, 96, 2112-2118. [Google Scholar] [CrossRef] [PubMed]
[35] Hagström, E., Lundgren, E., Lithell, H., et al. (2002) Normalized Dyslipidaemia after Parathyroidectomy in Mild Primary Hyperparathyroidism: Population-Based Study over Five Years. Clinical Endocrinology, 56, 253-260. [Google Scholar] [CrossRef] [PubMed]
[36] Godang, K., Lundstam, K., Mollerup, C., et al. (2018) The Effect of Surgery on Fat Mass, Lipid and Glucose Metabolism in Mild Primary Hyperparathyroidism. Endocrine Connections, 7, 941-948. [Google Scholar] [CrossRef] 
[37] Schillaci, G., Pucci, G., Pirro, M., et al. (2011) Large-Artery Stiffness: A Reversible Marker of Cardiovascular Risk in Primary Hyperparathyroidism. Atherosclerosis, 218, 96-101. [Google Scholar] [CrossRef] [PubMed]
[38] Tuna, M.M., Doğan, B.A., Arduç, A., et al. (2015) Impaired Endothelial Function in Patients with Mild Primary Hyperparathyroidism Improves after Parathyroidectomy. Clinical Endocrinology, 83, 951-956. [Google Scholar] [CrossRef] [PubMed]
[39] Ekmekci, A., Abaci, N., Colak Ozbey, N., et al. (2009) Endothelial Function and Endothelial Nitric Oxide Synthase Intron 4a/B Polymorphism in Primary Hyperparathyroidism. Journal of Endocrinological Investigation, 32, 611-616. [Google Scholar] [CrossRef] 

为你推荐